QuantuMDx Group Ltd has announced plans to expand the potential of its Q-POC™ technology and develop a quality control analytics system for cell and gene therapies (“C&GT”s), to be evaluated by GlaxoSmithKline’s C&GT platform group.

Press Release: 17 April 2019

QuantuMDx Group Ltd has announced plans to expand the potential of its Q-POC™ technology and develop a quality control analytics system for cell and gene therapies (“C&GT”s), to be evaluated by GlaxoSmithKline’s C&GT platform group.

Quality control testing for autologous

Read More